GlassScriptPhysician profile
Rojymon Jacob
NPI 1982687596
$1,361.87
in general payments reported to CMS, 2019-2025
14 companies · $182 in 2025
The $182 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $378 · 2020: $14.68 · 2021: $155 · 2022: $118 · 2024: $516 · 2025: $182.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $697.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $697.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Siemens Medical Solutions USA, INC. | $274.46 | 2024 | Varian Ethos Treatment Planning, Varian Treatment |
| Elekta, INC. | $264.73 | 2024-2025 | Elekta Medical Linear Accelerator, Leksell Gamma Knife Icon |
| Rigel Pharmaceuticals, INC. | $228.85 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $179.49 | 2019-2024 | Tagrisso |
| Alexion Pharmaceuticals, INC. | $100.00 | 2019 | |
| Varian Medical Systems, INC. | $89.17 | 2019 | |
| Novocure INC. | $56.39 | 2025 | Optune Gio |
| Exelixis INC. | $34.57 | 2019 | |
| Janssen Biotech, INC. | $30.04 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.42 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $28.01 | 2019-2020 | |
| Kite Pharma, INC. | $22.55 | 2019 | |
| Eisai INC. | $13.59 | 2022 | |
| Amgen INC. | $11.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rojymon Jacob listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.